A rare immunodeficiency discovered just 10 years ago now has its first treatment. The FDA has approved a Pharming Group drug developed to treat activated phosphoinositide 3-kinase delta syndrome, or ...
The U.S. Food and Drug Administration (FDA) on Friday issued a Complete Response Letter (CRL) to Pharming Group’s (NASDAQ: PHAR) supplemental New Drug Application (sNDA) for Joenja (leniolisib) for ...
(RTTNews) - Pharming Group (PHAR), a biopharmaceutical company, announced that the FDA has declined to approve the supplemental New Drug Application for Joenja as a treatment for children aged 4 to 11 ...
On Wednesday, Pharming Group N.V. (NASDAQ:PHAR) revealed topline results of data from its Phase 3 trial evaluating leniolisib in children aged 4 to 11 years with activated phosphoinositide 3-kinase ...
Shares of Pharming Group NV (NASDAQ:PHAR) dropped around 16.8% in premarket trading on Monday after the company disclosed that it received a Complete Response Letter (CRL) from the U.S. Food and Drug ...
Shares of Pharming Group fell after the Food and Drug Administration requested more information from the company on Joenja, its candidate to treat a rare immunodeficiency in children. Shares were down ...
The FDA issued complete response letters (CRLs) to two companies in recent days, resulting in vastly different reactions from the market. The U.S. regulator rejected Pharming’s bid to gain an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results